Clinical trial
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
NCT00477282 · BioNumerik Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00477282 |
|---|---|
| Title | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer |
| Official title | A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer |
| Lead sponsor | BioNumerik Pharmaceuticals, Inc., Industry |
| Collaborators | Crown Bioscience Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Karenitecin, Topotecan |
| Enrollment | 509 |
| Start date | Aug 1, 2007 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | May 23, 2007 |
| Last update posted | Mar 12, 2020 |
| Countries | Hungary, Lithuania, Poland, Romania, Russia |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: